Beijing GD Initiative Cell Therapy Technology Co.，Ltd. Report issue

Government Phase 1

Organization Overview

First Clinical Trial
2019
NCT04028440
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Beijing GD Initiative Cell Therapy Technology Co., Ltd. | Beijing GD Initiative Cell Therapy Technology Co.，Ltd.

Active Ingredients

Drugs in Phase 1 Trials (2)

allogeneic gamma-delta t cells (2 trials)

gamma-delta t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 2